RESONATE-2 follow up: ibrutinib and chlorambucil 5 years on

Jan Burger, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the follow up to the RESONATE-2 trial (NCT01722487, NCT01724346), which investigates the use of ibrutinib and chlorambucil for chronic lymphocytic leukemia (CLL). Five years after the initial investigation, 70% of participants taking ibrutinib showed progression-free survival compared to 12% with chlorambucil. Those in higher-risk groups also showed equal survival to those in lower-risk groups. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.